Supreme Court Maintains Telehealth Access for Mifepristone 

New York – Today, the Supreme Court maintained telehealth access for mifepristone as Louisiana v. FDA continues. National Institute for Reproductive Health President Christian LoBue released the following statement: 

“The Supreme Court’s decision to maintain telehealth access to mifepristone preserves a critical pathway to care, including for patients living in states with abortion bans for whom telehealth can be a critical access point. It does not, however, erase the broader threat facing medication abortion care. 

“Telehealth has been a critical pathway to care, particularly for people in rural areas and those navigating travel to clinics, time off work, or child care. The evidence has long shown that mifepristone is safe, effective, and an essential part of reproductive and miscarriage care. 

“This case continues, and Trump and his allies will also continue their attacks. The fact that patients’ ability to access this medication can hinge on week‑to‑week court decisions and the whims of anti-abortion politicians underscores how relentless the attack on reproductive freedom has become. States committed to defending reproductive freedom must act now to defend against future attacks by shielding providers from out-of-state prosecution for providing  abortion care, safeguarding patient data from surveillance, and ensuring that people can afford care in the face of escalating attacks.” 

Over 100 studies show mifepristone is safe and effective. Telehealth has been a critical access point — especially for patients who live in rural areas or who can’t take time off work. While the case continues, mifepristone can still be prescribed in person and via telehealth. 

While future federal actions keep mifepristone access at risk, additional details on state and local policies that can help guard against future attacks can be found here. 

###